Back to Search Start Over

Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues

Authors :
Roberto Attanasio
Alessandro Bozzao
Laura De Marinis
Michele Zini
Maria Rosaria Ambrosio
Giovanni Lasio
Maurizio Poggi
Laurence Katznelson
Edoardo Guastamacchia
Vincenzo Toscano
Francesco Logoluso
Renato Cozzi
Pietro Maffei
Ernesto De Menis
Andrea Lania
Philippe Chanson
Source :
Endocrine, Metabolic & Immune Disorders Drug Targets
Publication Year :
2020
Publisher :
Bentham Science Publishers Ltd., 2020.

Abstract

Acromegaly is a rare disease. Improvements in lifespan in these patients have recently been reported due to transsphenoidal surgery (TSS), advances in medical therapy, and strict criteria for defining disease remission. This document reports the opinions of a group of Italian experts who have gathered together their prolonged clinical experience in the diagnostic and therapeutic challenges of acromegaly patients. Both GH and IGF-I (only IGF-I in those treated with Pegvisomant) are needed in the diagnosis and follow-up. Comorbidities (cardio-cerebrovascular disease, sleep apnea, metabolic derangement, neoplasms, and bone/joint disease) should be specifically addressed. Any newly diagnosed patient should be referred to a multidisciplinary team experienced in the treatment of pituitary adenomas.

Details

ISSN :
18715303
Volume :
20
Database :
OpenAIRE
Journal :
Endocrine, Metabolic & Immune Disorders - Drug Targets
Accession number :
edsair.doi.dedup.....6b44d9f1e3e9b1c2a47e4a5971ca8c0a